Coupling of bone resorption and formation by RANKL reverse signalling

Abstract

Receptor activator of nuclear factor-kappa B (RANK) ligand (RANKL) binds RANK on the surface of osteoclast precursors to trigger osteoclastogenesis. Recent studies have indicated that osteocytic RANKL has an important role in osteoclastogenesis during bone remodelling; however, the role of osteoblastic RANKL remains unclear. Here we show that vesicular RANK, which is secreted from the maturing osteoclasts, binds osteoblastic RANKL and promotes bone formation by triggering RANKL reverse signalling, which activates Runt-related transcription factor 2 (Runx2). The proline-rich motif in the RANKL cytoplasmic tail is required for reverse signalling, and a RANKL(Pro29Ala) point mutation reduces activation of the reverse signalling pathway. The coupling of bone resorption and formation is disrupted in RANKL(Pro29Ala) mutant mice, indicating that osteoblastic RANKL functions as a coupling signal acceptor that recognizes vesicular RANK. RANKL reverse signalling is therefore a potential pharmacological target for avoiding the reduced bone formation associated with inhibition of osteoclastogenesis.

First in Mice: RANKL Neutralization in Fibrous Dysplasia

“…The fact these dramatic changes were initiated by osteoclast/giant cell inhibition lends support to the concept that osteoclasts and giant cells play a direct role in FD lesion formation and expansion. This key finding is consistent with recent evidence that osteoclast‐mediated osteoclast/osteogenic cell cross‐talk plays a central role in normal (and possibly dysplastic) bone biology …”

Masseter muscle atrophy impairs bone quality of the mandibular condyle but not the alveolar process early after induction

“…This putative mechanism of action could explain the beneficial effects of static compressive loading on preventing the subchondral bone loss after BoNTA intervention in young adult female mice by promoting the recovery of cell proliferation in the mandibular cartilage . Considering that the Receptor Activator for Nuclear Factor κ B Ligand (RANKL), a bone resorption promoter expressed by bone cells and chondrocytes, has been linked with bone loss after BoNTA injection in the associated muscles, the main source to explain its local and rapid expression at the mandibular condyle during BoNTA‐induced masseter atrophy remains to be further explored.…”

Melatonin: Another avenue for treating osteoporosis?

“…They found that exogenous administration of melatonin significantly suppresses wear debris‐induced bone resorption and the expression of inflammatory cytokines in vivo. RANKL, a transmembrane protein from the tumor necrosis factor (TNF) superfamily, is able to bind RANK on the surface of osteoclast precursors to trigger osteoclastogenesis . Chen et al discovered that RANKL signaling inhibits osteogenesis by promoting β‐catenin degradation and inhibiting its synthesis, which further suppresses osteogenic differentiation of BMSC.…”